Showing results (11-20 of 166) with videos related to
Sort By:
Pageof 17
Acta Oncologica (Stockholm, Sweden)|June 11, 2014
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma RegistryFredrik Ellin, Mats Jerkeman, Hans Hagberg, et al.European Journal of Haematology|October 15, 2010
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapySari Riihijärvi, Minna Taskinen, Mats Jerkeman, et al.Leukemia & Lymphoma|July 2, 2011
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry studyTove Wästerlid, Björn Jonsson, Hans Hagberg, et al.Experimental Hematology & Oncology|August 14, 2019
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomideAlexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, et al.Hematological Oncology|December 4, 2024
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell LymphomaÅsa Lindberg, Åsa Johansson, Fredrik Kahn, et al.Acta Oncologica (Stockholm, Sweden)|April 7, 2015
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based studyGustaf Hedström, Stefan Peterson, Mattias Berglund, et al.Hematological Oncology|May 6, 2017
Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry studyFredrik Ellin, Mats Jerkeman, Jenny Törnqvist, et al.Anticancer Research|March 6, 2020
Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian WomenSelamawit Mekuria, Mats Jerkeman, Ola Forslund, et al.Blood Advances|June 16, 2018
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)Kristina Drott, Hans Hagberg, Karin Papworth, et al.Journal of Internal Medicine|October 8, 2021
Advances in immune therapies in hematological malignanciesLuca Mazzarella, Gunilla Enblad, Johanna Olweus, et al.Pageof 17